PATENT CLAIM ANALYSIS

Application Number: 15756824
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["424", "133100"]

Abstract:
Provided are a monoclonal antibody specific for BQ323636.1, and its use for prediction of tamoxifen resistance in breast cancer patients.

Claim (Index 17):
The method according to  claim 16 , wherein the splice variant of NCOR2 is contacted with the antibody or antibody fragment that specifically recognizes the splice variant of NCOR2 in an immunoassay selected from the group consisting of radioimmunoassay, western blot assay, immunofluorescent assay, enzyme immunoassay, immunoprecipitation, chemiluminescent assay, immunohistochemical assay, dot blot assay, and slot blot assay.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 90.0
- Lexical Diversity: 1.04762
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14429657', '10591199', '13568145', '13177523', '12825057']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7582840342031376
- 35 USC 102 Novelty (BERT): 0.5065873364252027
- Combined Prediction Score: 0.7331143644253442
- Mean Citation Score: 266.799774
- Max Citation Score: 274.01337
- Similarity Product: 191.4703753273201

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test